References
- Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8(Suppl 7): 1–96
- Cady RK, Lipton RB, O'Quinn S, et al. Treatment of “mild” pain with sumatriptan in the spectrum of headaches in patients with disabling IHS migraine. (Abstr) Neurology 1999; 52(6 Suppl 2): A205–6
- Mathew NT, Kurman R, Perez F. Drug induced refractory headache: clinical features and management. Headache 1990; 30(10): 634–8
- Dihydroergotamine Nasal Spray Multicenter Investigators. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache 1995, 35(4): 177–84
- Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53(2): 180–4
- Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994: 44(9): 1587–92
- Ward TN. Management of an acute primary headache. Clin Neurosci 1998; 5(1): 50–4
- Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325 (5): 316–21
- Mathew NT, Asgharnejad M, Peykamian M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, crossover study. Neurology 1997; 49(6): 1485–90
- Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache 1998; 38: 737–47
- Bille B, Ludrigsson J, Sanner G. Prophylaxis of migraine in children. Headache 1977; 17(2): 61–3
- Lipton RB, Silberstein SD. Why study the comorbidity of migraine? Neurology 1994; 44(10 Suppl 7): S4–5